Brief: PTC Therapeutics To Sell Half Of Retained Royalties On Roche's Evrysdi To Royalty Pharma Unit
20/06/2024 14:43
June 20 (Reuters) - PTC Therapeutics Inc PTCT.O :
* ROYALTY PHARMA: PTC THERAPEUTICS EXERCISED OPTION TO SELL
HALF
OF RETAINED ROYALTIES ON ROCHE'S EVRYSDI TO CO'S UNIT FOR ABOUT
$242 MILLION UPFRONT
Source text for Eikon: ID:n0001193125-24-164004
Further company coverage: PTCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)